In general, to participate in the study, patients must be 18 years or older, have an expected life expectancy of > 12 weeks, WHO performance status 0-2, LVEF by MUGA > 50%, adequate organ function: hematological (ANC > 1.5X 10^9/L, platelets > 100 x 10^9/L, hepatic (bilirubin < 1.5 x ULN, AST/ALT < 3 x ULN), renal (calculated creatinine clearance > 60 ml/min). Negative pregnancy test for females with child-bearing potential. Prior radiotherapy allowed but must be delivered to < 25% of bone marrow, must be completed > 4 weeks before study entry and patients must have recovered from all side effects of the radiotherapy. Radiation must not be delivered to the sole response indicator lesion, unless there is documented evidence of disease progression in that site after completion of radiation. Patients must be able to reliably tolerate and comply with oral/feeding tube administered medications (patients are considered eligible if the investigator deems that there is no malabsorption syndrome and no GI obstruction that would impair the delivery of orally administered chemotherapy). If patient has had prior anthracycline, cumulative dose must be < 300mg/m2 of doxorubicin or its equivalent.